BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 22909997)

  • 1. Characteristics, therapy and outcome in an unselected and prospectively registered cohort of pancreatic cancer patients.
    Bjerregaard JK; Mortensen MB; Schønnemann KR; Pfeiffer P
    Eur J Cancer; 2013 Jan; 49(1):98-105. PubMed ID: 22909997
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Characteristics, therapy and outcome in an unselected and prospectively registered cohort of patients with gastro-oesophageal cancer.
    Schønnemann KR; Mortensen MB; Bjerregaard JK; Fristrup C; Pfeiffer P
    Acta Oncol; 2014 Mar; 53(3):385-91. PubMed ID: 23957622
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Value of combined therapy in pancreatic cancer with a poor prognosis: analysis of 233 clinical cases].
    Wang Y; Zhao P; Wang CF; Shan Y; Zhao DB; Tian YT; Sun YM; Che X; Zhang JW
    Zhonghua Yi Xue Za Zhi; 2009 Sep; 89(34):2381-5. PubMed ID: 20137689
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The impact of resection margin status and postoperative CA19-9 levels on survival and patterns of recurrence after postoperative high-dose radiotherapy with 5-FU-based concurrent chemotherapy for resectable pancreatic cancer.
    Kinsella TJ; Seo Y; Willis J; Stellato TA; Siegel CT; Harpp D; Willson JK; Gibbons J; Sanabria JR; Hardacre JM; Schulak JP
    Am J Clin Oncol; 2008 Oct; 31(5):446-53. PubMed ID: 18838880
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Significance of pathologic response to preoperative therapy in pancreatic cancer.
    Chun YS; Cooper HS; Cohen SJ; Konski A; Burtness B; Denlinger CS; Astsaturov I; Hall MJ; Hoffman JP
    Ann Surg Oncol; 2011 Dec; 18(13):3601-7. PubMed ID: 21947697
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Expression of S100A2 calcium-binding protein predicts response to pancreatectomy for pancreatic cancer.
    Biankin AV; Kench JG; Colvin EK; Segara D; Scarlett CJ; Nguyen NQ; Chang DK; Morey AL; Lee CS; Pinese M; Kuo SC; Susanto JM; Cosman PH; Lindeman GJ; Visvader JE; Nguyen TV; Merrett ND; Warusavitarne J; Musgrove EA; Henshall SM; Sutherland RL;
    Gastroenterology; 2009 Aug; 137(2):558-68, 568.e1-11. PubMed ID: 19376121
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adjuvant therapy and survival after resection of pancreatic adenocarcinoma: a population-based analysis.
    Mayo SC; Austin DF; Sheppard BC; Mori M; Shipley DK; Billingsley KG
    Cancer; 2010 Jun; 116(12):2932-40. PubMed ID: 20336787
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Resection status, age and nodal involvement determine survival among patients receiving adjuvant chemoradiotherapy in pancreatic adenocarcinoma.
    Moghanaki D; Mick R; Furth EE; Sohal D; Salmon PM; Behbahani A; Morgans AK; Miller SM; Giantonio BJ; Whittington RW; Haller DG; Rosato EF; Plastaras JP
    JOP; 2011 Sep; 12(5):438-44. PubMed ID: 21904068
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Multimodality therapy for pancreatic cancer in the U.S. : utilization, outcomes, and the effect of hospital volume.
    Bilimoria KY; Bentrem DJ; Ko CY; Tomlinson JS; Stewart AK; Winchester DP; Talamonti MS
    Cancer; 2007 Sep; 110(6):1227-34. PubMed ID: 17654662
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pancreatic carcinoma deemed unresectable at exploration may be resected for cure: an institutional experience.
    Chao C; Hoffman JP; Ross EA; Torosian MH; Eisenberg BL
    Am Surg; 2000 Apr; 66(4):378-85; discussion 386. PubMed ID: 10776876
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sequential and/or concurrent hypofractionated radiotherapy and concurrent chemotherapy in neoadjuvant treatment of advanced adenocarcinoma of the pancreas. Outcome and patterns of failure.
    Zimmermann FB; Schuhmacher C; Lersch C; Bernhardt B; Pickel P; Siewert JR; Molls M; Jeremic B
    Hepatogastroenterology; 2004; 51(60):1842-6. PubMed ID: 15532839
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adjuvant radiotherapy and chemotherapy for pancreatic carcinoma: the Mayo Clinic experience (1975-2005).
    Corsini MM; Miller RC; Haddock MG; Donohue JH; Farnell MB; Nagorney DM; Jatoi A; McWilliams RR; Kim GP; Bhatia S; Iott MJ; Gunderson LL
    J Clin Oncol; 2008 Jul; 26(21):3511-6. PubMed ID: 18640932
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neoadjuvant therapy for resectable pancreatic cancer.
    Raut CP; Evans DB; Crane CH; Pisters PW; Wolff RA
    Surg Oncol Clin N Am; 2004 Oct; 13(4):639-61, ix. PubMed ID: 15350939
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chemoradiation followed by chemotherapy before resection for borderline pancreatic adenocarcinoma.
    Brown KM; Siripurapu V; Davidson M; Cohen SJ; Konski A; Watson JC; Li T; Ciocca V; Cooper H; Hoffman JP
    Am J Surg; 2008 Mar; 195(3):318-21. PubMed ID: 18308038
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Survival after pancreatectomy for pancreatic adenocarcinoma is not impacted by performance status.
    Mullinax JE; Hernandez JM; Toomey P; Villadolid D; Bowers C; Cooper J; Rosemurgy AS
    Am J Surg; 2012 Nov; 204(5):704-8. PubMed ID: 23140830
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of neoadjuvant therapy on local recurrence after resection of pancreatic adenocarcinoma.
    Greer SE; Pipas JM; Sutton JE; Zaki BI; Tsapakos M; Colacchio TA; Gibson JJ; Wiener DC; Ripple GH; Barth RJ
    J Am Coll Surg; 2008 Mar; 206(3):451-7. PubMed ID: 18308215
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The impact of lymph node number on survival in patients with lymph node-negative pancreatic cancer.
    Hellan M; Sun CL; Artinyan A; Mojica-Manosa P; Bhatia S; Ellenhorn JD; Kim J
    Pancreas; 2008 Jul; 37(1):19-24. PubMed ID: 18580439
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pancreatic head carcinoma: is pancreatic resection indicated for patients with stage III pancreatic duct cancer?
    Lygidakis NJ; Papadopoulou P
    Hepatogastroenterology; 1995; 42(5):587-96. PubMed ID: 8751219
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Factors affecting treatment delivery and outcomes of patients with early-stage pancreatic adenocarcinoma.
    Vanderveen KA; Canter RJ; Yin D; Cress RD; Bold RJ
    Pancreas; 2011 Apr; 40(3):480-2. PubMed ID: 21412120
    [No Abstract]   [Full Text] [Related]  

  • 20. Prognostic factors in resected pancreatic adenocarcinoma: analysis of actual 5-year survivors.
    Cleary SP; Gryfe R; Guindi M; Greig P; Smith L; Mackenzie R; Strasberg S; Hanna S; Taylor B; Langer B; Gallinger S
    J Am Coll Surg; 2004 May; 198(5):722-31. PubMed ID: 15110805
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.